TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03932708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC Core Elements of Outpatient Stewardship
Description: The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
Study: NCT00670059

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: single embryo transfer without aneuploidy screening
Description: without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: single embryo transfer with aneuploidy screening
Description: with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
Study: NCT04630548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine copper device
Description: The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine copper device
Description: The obstetrical team will identify subjects who present in labor who meet the criteria and express interest in intrauterine contraception. Immediately after cesarean delivery, consented subjects will be randomized to immediate post placental IUD placement within 10 minutes or IUD placement at their routine standard postpartum visit (6 to 8 weeks postpartum).
Study: NCT00569985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Description: Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
Study: NCT00966576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Description: 1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
Study: NCT01130272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Tablets, orally, twice daily.
Study: NCT02407444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy treatment & music listening
Description: All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes.
Study: NCT02222428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL/BI 54903 XX FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 54903 XX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL
Study: NCT04112251

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavonols Supplement
Description: Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa Flavonols Supplement
Description: Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
Study: NCT04313608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab in combination with gemcitabine and oxaliplatin for up to 8 cycles, followed by up to 4 cycles of glofitamab monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV oxaliplatin after gemcitabine administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive IV mosunetuzumab in combination with gemcitabine and oxaliplatin for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a single dose of IV obinutuzumab 7 days prior to the first administration of glofitamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
Study: NCT02090829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon (synthetic oxytocin)
Description: Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).
Study: NCT04653220

Intervention type: OTHER
Group type: OTHER
Intervention: Control 1
Description: 25g glucose dissolve in 250ml of water
Study: NCT05811962

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, only comparison
Study: NCT04653220

Intervention type: OTHER
Group type: OTHER
Intervention: Control 2
Description: 25g glucose dissolve in 250ml of water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Crokao
Description: Standard Crokao containing 25g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 1
Description: Low sugar variant 1 containing 25g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 2
Description: Low sugar variant 2 containing 25g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 3
Description: Low sugar variant 3 containing 25g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 4
Description: Low sugar variant 4 containing 25g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar variant 5
Description: Low sugar variant 5 containing 25g of available carbohydrate
Study: NCT01884025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Moving and Get Well
Description: Walking Class

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health and Humor Class
Description: Class about the role of humor in health
Study: NCT00514137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
Study: NCT04871880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian led life style modification intervention
Description: All participants received recommendations for a low-fat hypocaloric diet that was 750 kcal/day less than their daily energy need which supervised by dietitians. Additionally, patients were encouraged to walk 200 minutes per weeks and a short self-report questionnaire for the measurement of habitual physical activity was implemented at baseline, 4, 16, 32 and 48 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional care (control)
Description: Receive routine care
Study: NCT03980483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg
Description: Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cap (containing lactose) to be administered orally.
Study: NCT03513393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velpatasvir
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velpatasvir
Description: Test 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: velpatasvir
Description: Reference
Study: NCT01684410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 HC 100 mg
Description: Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
Study: NCT01130272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Tablets, orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Tablets, orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Tablets, orally, twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets twice daily.
Study: NCT02654678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril Orodispersible Minitablet
Description: Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
Study: NCT01721798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena levonorgestrel IUD
Description: Intrauterine contraception system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T-380a IUD
Description: intrauterine contraception system
Study: NCT02617537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP(YAZ,BAY86-5300)
Description: 0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for 28 days per 28-day intake cycle
Study: NCT01962675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation + step training
Description: Direct current stimulation of motor cortex with low stimulation intensity

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation + step training
Description: Stepping over specified soft foam obstacles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct current stimulation + step training
Description: Stepping over specified soft foam obstacles
Study: NCT03521310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin-to-skin
Description: Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Neonates will get Conventional care the first 72 hours after birth
Study: NCT00336544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cethromycin
Description: Cethromycin 300 mg once per day (QD) for 7 days, administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Study: NCT03699592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reach Home and Read Toolkit
Description: The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
Study: NCT02870868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: Slow breathing techniques from yoga

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow breathing
Description: Slow breathing techniques from yoga
Study: NCT04457856

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: TJ003234 injection
Description: Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TJ003234 injection
Description: Intravenous administration, single dose (0.3-1-3-10mg/kg) or multiple dose (1-3-6mg/kg, once every week, for 8 weeks)
Study: NCT01627132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: 100mg QD
Study: NCT02119299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART device
Description: Sensor Monitored Alimentary Restriction Therapy (SMART) device
Study: NCT02188550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus and letrozole
Description: This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally
Study: NCT04260165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Row Carpectomy
Description: Excision of the proximal carpal row - the scaphoid, lunate and triquetrum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-corner fusion
Description: Scaphoid excision and four-corner fusion with cannulated headless compression screws/dorsal plate
Study: NCT02105324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Automated blood glucose control via a closed-loop bionic pancreas device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: As a comparator control, usual diabetes camp care with the participant's own insulin pump.
Study: NCT00701831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: The dose is titrated according to patient needs
Study: NCT03885973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: Fermented milk containing probiotic Lactobacillus plantarum for three weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fermented milk containing placebo for three weeks
Study: NCT03895801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFX-1
Description: intravenously administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IFX-1
Description: intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-IFX-1
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid (GC)
Description: orally administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoid (GC)
Description: orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Glucocorticoid (Placebo-GC)
Description: orally administered
Study: NCT00299039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen plus codeine
Description: capsules four times daily until pain free or for a maximum of seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen plus ibuprofen
Description: capsules four times daily until pain free or for a maximum of seven days
Study: NCT03885557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Experimental DOS
Description: After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group II SS group
Description: After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
Study: NCT03220503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial injury
Description: single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
Study: NCT01398241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5267683
Description: Multiple ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple ascending doses
Study: NCT03170713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arveles
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arveles
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: arveles
Description: 800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrafen
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrafen
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrafen
Description: 800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebos
Description: 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebos
Description: 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
Study: NCT01068236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle managment
Description: Exercise, yoga, food diaries, provider consultation